Journal of Cancer Survivorship

, Volume 3, Issue 4, pp 233–240 | Cite as

Longitudinal assessment of BMI in relation to ADT use among early stage prostate cancer survivors

  • Gregory P. Beehler
  • Michael Wade
  • Borah Kim
  • Lynn Steinbrenner
  • Laura O. Wray
Article

Abstract

Introduction

The use of androgen deprivation therapy (ADT) for prostate cancer is on the rise, but its adverse side effects may include increased fat mass and decreased lean muscle mass. The net effect of ADT on BMI is unknown.

Methods

Primary, incident cases of early stage prostate cancer (n = 473) were identified from the Buffalo VA Medical Center tumor registry and matched to body size, demographic, comorbidity, and treatment exposure data from veteran medical records. Multilevel modeling was used to assess the association between ADT and changes in BMI.

Results

On average, survivors were overweight at diagnosis and showed small, non-significant changes in BMI over time. However, among those survivors with a history of ADT, a significant decrease of 0.05 BMI units per year was associated with each additional dose of ADT (p < 0.001). When the association between BMI rate of change and ADT was allowed to vary with respect to age, additional doses of ADT predicted stronger decreases in BMI for younger survivors as compared to older survivors (p < 0.05). Neither a history of surgery nor radiation influenced the association between ADT use and BMI.

Conclusions

Declines in BMI in relation to ADT exposure may be reflective of unfavorable changes in body composition, especially decreased muscle mass, that is most pronounced in younger survivors.

Implications for Cancer Survivors

Survivors on ADT may benefit from close monitoring of physical functioning and referral for exercise interventions to preserve muscle mass and improve health related quality of life.

Keywords

Androgen deprivation therapy Body mass index Cancer survivorship Longitudinal studies Prostatic neoplasms 

References

  1. 1.
    Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975–2004. 2007. Based on November 2006 SEER data submission.Google Scholar
  2. 2.
    VA National Tumor Registry. Consolidated Data Summary Report. http://vaww1.va.gov/cancer/docs/SUMM2006.doc. Accessed December, 2008.
  3. 3.
    Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148(6):435–48.PubMedGoogle Scholar
  4. 4.
    Kawakami J, Cowan JE, Elkin EP, et al. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer. 2006;106(8):1708–14.CrossRefPubMedGoogle Scholar
  5. 5.
    Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300(2):173–81.CrossRefPubMedGoogle Scholar
  6. 6.
    Kintzel PE, Chase SL, Schultz LM, et al. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008;28(12):1511–22.CrossRefPubMedGoogle Scholar
  7. 7.
    Mohile SG, Mustian K, Bylow K, et al. Management of complications of androgen deprivation therapy in older men. Crit Rev Oncol/Hematol. 2009;70(3):235–55.Google Scholar
  8. 8.
    Basaria A, Lieb J, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol. 2002;56:779–86.CrossRefGoogle Scholar
  9. 9.
    Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599–603.CrossRefPubMedGoogle Scholar
  10. 10.
    Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96:1358–67.PubMedCrossRefGoogle Scholar
  11. 11.
    Miller DC, Sanda MG, Dunn RL, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005;23(12):2772–80.CrossRefPubMedGoogle Scholar
  12. 12.
    Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–61.CrossRefPubMedGoogle Scholar
  13. 13.
    Stroup SP, Cullen J, Auge BK, et al. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix Consensus Definition. Cancer. 2007;110:1003–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Wright ME, Chang S-C, Schatzkin A, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer. 2007;109(4):675–84.CrossRefPubMedGoogle Scholar
  15. 15.
    Rodriguez C, Patel AV, Calle EE, et al. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomark Prev. 2001;10:345–53.Google Scholar
  16. 16.
    Gong Z, Agalliu I, Lin DW, et al. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer. 2007;109:1192–202.CrossRefPubMedGoogle Scholar
  17. 17.
    Peeters AP, Barendregt JJP, Willekens FP, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med. 2003;138(1):24–32.PubMedGoogle Scholar
  18. 18.
    Flegal KM, Graubard BI, Williamson DF, et al. Impact of smoking and preexisting illness on estimates of the fractions of deaths associated with underweight, overweight, and obesity in the US population. Am J Epidemiol. 2007;166(8):975–82.CrossRefPubMedGoogle Scholar
  19. 19.
    Fitzpatrick JM. Management of localized prostate cancer in senior adults: the crucial role of comorbidity. BJU Int. 2008;101(Supplement 2):16–22.CrossRefPubMedGoogle Scholar
  20. 20.
    Houterman S, Janssen-Heijnen ML, Hendrikx AJ, et al. Impact of comorbidity on treatment and prognosis of prostate cancer patients: a population-based study. Crit Rev Oncol/Hematol. 2006;58(1):60–7.CrossRefGoogle Scholar
  21. 21.
    Fouad MN, Mayo CP, Funkhouser EM, et al. Comorbidity independently predicted death in older prostate cancer patients, more of whom died with than from their disease. J Clin Epidemiol. 2004;57(7):721–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Freeman VL, Durazo-Arvizu R, Arozullah AM, et al. Determinants of mortality following a diagnosis of prostate cancer in Veterans Affairs and private sector health care systems. Am J Public Health. 2003;93(10):1706–12.CrossRefPubMedGoogle Scholar
  23. 23.
    Das SR, Kinsinger LS, Yancy WS Jr, et al. Obesity prevalence among veterans at Veterans Affairs medical facilities. Am J Prev Med. 2005;28(3):291–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Wang A, Kinsinger LS, Kahwati LC, et al. Obesity and weight control practices in 2000 among veterans using VA facilities. Obes Res. 2005;13(8):1405–11.PubMedGoogle Scholar
  25. 25.
    Nelson KM. The burden of obesity among a national probability sample of veterans. J Gen Intern Med. 2006;21(9):915–9.CrossRefPubMedGoogle Scholar
  26. 26.
    NCI. Facing forward: Life after cancer treatment. http://www.cancer.gov/cancertopics/life-after-treatment/page3#b3. Accessed December, 2008.
  27. 27.
    Davies BJ, Walsh TJ, Ross PL, et al. Effect of BMI on primary treatment of prostate cancer. Urology. 2008;72:406–11.CrossRefPubMedGoogle Scholar
  28. 28.
    SAS Institute Inc., SAS 9.2. Cary, NC: 2002–2008.Google Scholar
  29. 29.
    Hellerstedt BA, Peinta KJ. The current state of hormonal therapy for prostate cancer. CA: a Cancer Journal for Clinicians. 2002;52:154–79.CrossRefGoogle Scholar
  30. 30.
    Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996;81:4358–65.CrossRefPubMedGoogle Scholar
  31. 31.
    Kapoor D, Jones TH. Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention? Drugs Aging. 2008;25:357–69.CrossRefPubMedGoogle Scholar
  32. 32.
    Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004;63:742–5.CrossRefPubMedGoogle Scholar
  33. 33.
    Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass, and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167:2361–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 2001;86:2787–91.CrossRefPubMedGoogle Scholar
  35. 35.
    van Londen GJ, Levy ME, Perera S, et al. Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study. Crit Rev Oncol/Hematol. 2008;68(2):172–7.CrossRefGoogle Scholar
  36. 36.
    Earle CC. Long term care planning for cancer survivors: a health services research agenda. Journal of Cancer Survivorship. 2007;1:64–74.CrossRefPubMedGoogle Scholar
  37. 37.
    Levy ME, Perera S, van Londen GJ, et al. Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study. Urology. 2008;71(4):735–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Moyad MA. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urologic Oncology: Seminars and Original Investigations. 2006;23:56–64.CrossRefGoogle Scholar
  39. 39.
    Doyle C, Kushi LH, Byers T, et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA: a Cancer Journal for Clinicians. 2006;56(6):323–53.CrossRefGoogle Scholar
  40. 40.
    Patterson RE, Neuhouser ML, Hedderson MM, et al. Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc. 2003;103(3):323–8.PubMedGoogle Scholar
  41. 41.
    Demark-Wahnefried W, Aziz NM, Rowland JH, et al. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol. 2005;23(24):5814–30.CrossRefPubMedGoogle Scholar
  42. 42.
    Jazieh AR, Foraida M, Ghouse M, et al. The impact of cancer diagnosis on the lifestyle and habits of patients served at a Veterans Administration Hospital. J Cancer Educ. 2006;21(3):147–50.CrossRefPubMedGoogle Scholar
  43. 43.
    Stevens VJ, Wagner EL, Rossner J, et al. Validity and usefulness of medical chart weights in the long-term evaluation of weight loss programs. Addict Behav. 1988;13:171–5.CrossRefPubMedGoogle Scholar
  44. 44.
    DiMaria-Ghalili R. Medical record versus researcher measures of height and weight. Biological Research for Nursing. 2006;8(1):15–23.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Gregory P. Beehler
    • 1
    • 2
  • Michael Wade
    • 3
  • Borah Kim
    • 1
  • Lynn Steinbrenner
    • 4
    • 5
  • Laura O. Wray
    • 1
    • 5
  1. 1.VISN 2 Center for Integrated Healthcare (116B)VA WNY Healthcare SystemBuffaloUSA
  2. 2.School of Public Health and Health Professions, University at BuffaloThe State University of New YorkBuffaloUSA
  3. 3.VISN 2 Center for Integrated HealthcareSyracuse VA Medical CenterSyracuseUSA
  4. 4.Oncology DepartmentVA Western New York Healthcare SystemBuffaloUSA
  5. 5.School of Medicine, University at BuffaloThe State University of New YorkBuffaloUSA

Personalised recommendations